POXEL As of December 31st, 2015, the cash and cash equivalents amounted to €42.4 million* compared to
€10.3 million on December 31st, 2014.
As expected, Poxel did not generate significant revenues in 2015.
These figures are consistent with the Company's expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.
*unaudited
Next financial press release: Year Full-Year Financial Statement, March 31st, 2016
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
Investor relations / Media - EU/US MacDougall Biomedical Communications Gretchen Schweitzer or Stephanie Maysmay@macbiocom.com + 49 89 2424 3494 or + 49 172 861 8540 | Investor relations / Media - France NewCap Florent Alba/Nicolas Mérigeau poxel@newcap.fr + 33 1 44 71 98 55 |
Poxel SA issued this content on 28 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 February 2016 11:49:11 UTC
Original Document: http://www.poxel.com/pdf/160128_YE2015_SalesTurnover_Final%5B3%5D.pdf
